The Rx symbol never reaches the record

Ask whether a device is prescription-only or available over the counter, and most regulatory teams answer instantly — it’s on the label, it was decided during development, everyone downstream just reads it off the box. Ask where that status lives in FDA’s own device records, and the honest answer is: nowhere structured. It is a labeling requirement, not a classification field, and the two are not the same thing.

One rule, two acceptable statements

21 CFR 801.109 sets the requirement directly: a prescription device’s label must bear either the symbol “Rx only” (or “℞ only”) or the statement “Caution: Federal law restricts this device to sale by or on the order of a” — filled in with physician, dentist, veterinarian, or whichever licensed practitioner the device is restricted to. The rule sits in Subpart D of Part 801, “Exemptions From Adequate Directions for Use,” because that is precisely what prescription status buys a device: an exemption from the general requirement in 801.5 that labeling carry directions a layperson could safely follow alone — on the premise that no such directions can be written for a device unsafe to use outside a practitioner’s supervision.

No field carries it

FDA’s public device classification record — regulation number, device class, review panel, medical specialty, the GMP-exemption and implant flags — describes what kind of device a product code covers, not who is allowed to buy one. The 510(k) and PMA databases are built the same way: applicant, decision date, predicate, panel. Prescription status is decided in the cleared labeling itself, a document the public record generally doesn’t reproduce in structured form — not in any field a search or an API query can filter on.

The label carries the answer. The record only carries that a device exists.

Rx to OTC is not an edit

FDA does not treat that gap as harmless. Its guidance on over-the-counter devices is direct: changing a device already cleared for prescription use into one labeled for OTC use ordinarily requires a new 510(k), because the directions adequate for a clinician and the directions adequate for a lay user are not the same showing. A second clearance for what looks like an identical device, filed years after the first, is routinely that determination being made — not a technology change, a use change.

The practice

A portfolio watch keyed to product code or regulation number will catch a second clearance sitting on top of the first one without difficulty — that part of the match is exactly what those fields are for. What it will not do on its own is say why the second filing exists. Distinguishing a prescription-to-OTC relabeling from a genuine design change means opening the submission and reading it, not inferring it from the fields a product-code match already returned. That reading is regulatory intelligence and method, never regulatory advice about a specific device or submission strategy — the determination belongs with your regulatory team.